Assenagon Asset Management
ANIK icon

Assenagon Asset Management’s Anika Therapeutics ANIK Stock Holding History

Assenagon Asset Management’s Portfolio ANIK Stock Details ANIK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$922K Buy
63,016
+16,430
+35% +$244K ﹤0.01% 982
2026
Q1 		$675K Buy
46,586
+33,951
+269% +$394K ﹤0.01% 960
2025
Q4 		$121K Sell
12,635
-33,208
-72% -$318K ﹤0.01% 1129
2025
Q3 		$431K Buy
+45,843
New +$438K ﹤0.01% 1075
2024
Q4 		– Sell
-50,745
Closed -$1.25M – 1323
2024
Q3 		$1.25M Buy
50,745
+3,733
+8% +$96.8K ﹤0.01% 1085
2024
Q2 		$1.19M Hold
47,012
– – ﹤0.01% 1052
2024
Q1 		$1.19M Sell
47,012
-12
-0% -$290 ﹤0.01% 1015
2023
Q4 		$1.07M Hold
47,024
– – ﹤0.01% 1078
2023
Q3 		$876K Hold
47,024
– – ﹤0.01% 1074
2023
Q2 		$1.22M Hold
47,024
– – ﹤0.01% 916
2023
Q1 		$1.35M Sell
47,024
-672
-1% -$20K ﹤0.01% 960
2022
Q4 		$1.41M Sell
47,696
-42,357
-47% -$1.2M 0.01% 942
2022
Q3 		$2.14M Hold
90,053
– – 0.01% 687
2022
Q2 		$2.01M Sell
90,053
-1,872
-2% -$41.8K 0.01% 832
2022
Q1 		$2.31M Sell
91,925
-37,578
-29% -$1.15M 0.01% 785
2021
Q4 		$4.64M Sell
129,503
-140,618
-52% -$5.63M 0.01% 535
2021
Q3 		$11.5M Buy
270,121
+89,100
+49% +$3.67M 0.04% 272
2021
Q2 		$7.84M Buy
181,021
+133,397
+280% +$5.68M 0.03% 387
2021
Q1 		$1.94M Buy
47,624
+6,336
+15% +$240K 0.01% 715
2020
Q4 		$1.87M Sell
41,288
-27,712
-40% -$1.05M 0.01% 539
2020
Q3 		$2.44M Buy
+69,000
New +$2.49M 0.01% 546
2020
Q2 		– Sell
-98,670
Closed -$2.85M – 1109
2020
Q1 		$2.85M Buy
98,670
+83,948
+570% +$3.4M 0.02% 293
2019
Q4 		$763K Buy
+14,722
New +$855K ﹤0.01% 609
2019
Q3 		– Sell
-12,273
Closed -$499K – 831
2019
Q2 		$499K Sell
12,273
-6,578
-35% -$240K ﹤0.01% 851
2019
Q1 		$570K Sell
18,851
-37,379
-66% -$1.28M 0.01% 792
2018
Q4 		$1.89M Buy
+56,230
New +$2.03M 0.02% 464

Other funds holding ANIK

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
CP
Caligan Partners New York $2.13B AUM 758.65% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
BFM
Boothbay Fund Management New York $7.6B AUM 109.3% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
CM
Capital Management Glen Allen, Virginia $666M AUM 17.17% 1-Year Est. Return

Assenagon Asset Management's ANIK Position: Q2 2026 in Review

Assenagon Asset Management increased its Anika Therapeutics (ANIK) stake by 35% in Q2 2026, buying an estimated $244K and bringing the position to 63,016 shares worth $922K. The position accounts for ﹤0.01% of the portfolio, ranked #982.

Assenagon Asset Management first reported a position in ANIK in Q4 2018 and has held it in 26 quarters since. The position peaked at $11.5M in Q3 2021. 133 funds tracked by Wall St. Rank hold ANIK as of Q2 2026.

  • Assenagon Asset Management held 63,016 shares of Anika Therapeutics worth $922K as of Q2 2026.
  • Assenagon Asset Management bought 16,430 Anika Therapeutics shares in Q2 2026, an estimated $244K.
  • Anika Therapeutics made up ﹤0.01% of Assenagon Asset Management's portfolio in Q2 2026, its #982 holding.
  • Assenagon Asset Management first reported a position in Anika Therapeutics in Q4 2018 and has held it in 26 quarters since.
  • Assenagon Asset Management's Anika Therapeutics position peaked at $11.5M in Q3 2021.
  • 133 funds tracked by Wall St. Rank held Anika Therapeutics as of Q2 2026.

Based on Assenagon Asset Management's 13F filing for Q2 2026, filed 8 Jul 2026.